Recent studies examine the burden of CRSwNP, looking at quality of life in patients and caregivers and assessing how CRSwNP ...
Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...
Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions, including ...
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
Zacks.com on MSN1d
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPDThe European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...
OptiNose (NASDAQ:OPTN) stock surges 61% as Paratek Pharmaceuticals agrees to a $330M acquisition. Read mroe here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback